Celsion Corporation (NASDAQ:CLSN) investor sentiment is getting stoked today on back of new bullish attention from Oppenheimer analyst Hartaj Singh. Even though this biotech company has drawn some critical fire circling lead program in ThermoDox in liver cancer, what has Singh making a strong bullish case for “OPTIMA(L) redemption?”
Story Continues
